Chosa Oncology (CHOSA) Q2 2026 earnings summary

Executive summary

• Advanced Platin-DRP® from clinical validation to preparations for commercialization, with strengthened presence in the US and new international collaborations in lung cancer and breast cancer.

• Presented significant clinical data at ASCO 2026, including validation of Platin-DRP® in lung and breast cancer, and established a US base in Kendall Square, Boston.

• Appointed Bill Cronin to lead US commercialization efforts post-period, aiming to accelerate Platin-DRP® market introduction.

Financial highlights

• Net result after financial items for Q2 2026 was -2,632 TSEK, compared to -1,967 TSEK in Q2 2025.

• Earnings per share after dilution was -0.03 SEK (Q2 2025: -0.028 SEK).

• Cash and cash equivalents as of June 30, 2026, amounted to 2,560 TSEK (June 30, 2025: 1,876 TSEK).

• Equity as of June 30, 2026, was 19,107 TSEK (June 30, 2025: 14,467 TSEK).

• Directed share issue in February 2026 raised 7.3 MSEK before transaction costs.

Outlook and guidance

• Focus for H2 2026 is on translating clinical evidence into commercial value, with ambitions to establish Platin-DRP® as a precision medicine tool for platinum-based cancer therapies.